Publications by authors named "G Lanzolla"
Ocular surface disease index in Graves' orbitopathy: a cross-sectional study.
Front Endocrinol (Lausanne)
December 2024
Introduction: Graves' Orbitopathy (GO) is an autoimmune disorder characterized by inflammation of orbital tissues, leading to various ocular manifestations, including ocular surface disease. This cross-sectional study aimed to assess the presence of ocular surface disease using the Ocular Surface Disease Index (OSDI) in patients with Graves' disease (GD) and moderate-to-severe active GO compared to those with GD and mild non-active GO. Additionally, we aimed to investigate the correlation between ocular surface disease and the eye features of GO.
View Article and Find Full Text PDFArticle Synopsis
- Estrogen deficiency contributes to conditions like primary ovarian insufficiency and postmenopausal osteoporosis, disrupting the balance of bone formation and resorption, leading to bone loss and a higher risk of fractures due to reduced trabecular bone mass.
- In the bone marrow, hypoxia-inducible factor-2α (HIF2) is vital for cell responses to low-oxygen conditions, and its loss in skeletal progenitors enhances trabecular bone mass by boosting bone formation.
- The study shows that PT2399, a HIF2 inhibitor, can prevent bone loss in estrogen-deficient mice by increasing the number of osteoblasts and expanding the skeletal progenitor cell pool, highlighting a key mechanism for bone formation and mass
Article Synopsis
- Sirolimus was found to help people with Graves' orbitopathy (a condition that affects the eyes) more than another medicine called methylprednisolone at the 24-week mark.
- In the study, 40 patients were treated, and researchers looked at how they felt and their eye symptoms over 48 weeks.
- While sirolimus showed better results at 24 weeks, both medicines had similar outcomes at 48 weeks, suggesting that longer treatment might be needed for better results.
Energy metabolism, through pathways such as oxidative phosphorylation (OxPhos) and glycolysis, plays a pivotal role in cellular differentiation and function. Our study investigates the impact of OxPhos disruption in cortical bone development by deleting mitochondrial transcription factor A (TFAM). TFAM controls OxPhos by regulating the transcription of mitochondrial genes.
View Article and Find Full Text PDFGraves disease: latest understanding of pathogenesis and treatment options.
Nat Rev Endocrinol
November 2024
Graves disease is the most common cause of hyperthyroidism in iodine-sufficient areas. The main responsible mechanism is related to autoantibodies that bind and activate the thyrotropin receptor (TSHR). Although Graves hyperthyroidism is relatively common, no causal treatment options are available.
View Article and Find Full Text PDF